Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Item

http://www.wikidata.org/entity/Q37045421

Q37045421

about

Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient.Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer.A Review of Fulvestrant in Breast Cancer.Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer.The role of abemaciclib in treatment of advanced breast cancer.Updates on managing advanced breast cancer with palbociclib combination therapy Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

P2860

Q37566023-6FB7EE0D-B211-4501-B631-F54D7F5EC655 Q37570653-63970412-51DD-4145-9C27-5086756E318A Q37632170-135C4385-B9EA-4251-BC7A-52CA8B6368D6 Q38649485-B2EEB4A4-C94F-41C1-80BA-983A7B1EAD95 Q38709347-FF133A25-F0E5-423D-AAC0-0C26492A4D26 Q38757501-F46C11A2-4478-4502-9574-1DBD61377669 Q38798302-CF54C432-129A-4B61-9650-222678311B21 Q39204274-415C9288-BBFA-47C7-AB12-283F5908A620 Q39294871-D28A0FEA-0F20-4756-B425-52838DF4984A Q39430455-525F7FF2-4C9F-4599-901A-04CC0C19D898 Q39433738-68CE7DFB-A1D9-4D01-8C80-33C8C6AC9924 Q41545718-12452A1C-898C-4B9E-94DA-F85ADC45C5C5 Q42346622-5120770D-27D3-4FCF-9A5B-2808B8E5E3B0 Q43281043-10404D2D-7524-430D-97D3-35CF42B28869 Q47316489-F5BB1A90-81CF-43F9-80D7-5B97D41C9317 Q47321016-FFEF8381-0858-4958-A9BC-E11EDF61C66B Q47393206-6D75BD44-6A5D-4C18-A794-43443DA974EC Q47561979-3457AFF5-6F86-4DD3-B530-5C4351B6A6D8 Q47578323-365DD676-F0FE-4181-8593-C29F76A6E795 Q47657661-2C4B29DB-3E25-4D4B-9D19-7FB1A883C7AB Q48157533-EAF76480-DB8B-465C-BA7E-04A734603FB3 Q48231208-A7B73D31-3169-495C-A400-AC7EC2674FC1 Q50001116-42A7D3E4-B008-4483-9D85-FD492F991F81 Q50093673-862DE188-AA72-4A2E-8720-9FEC08C9326C Q50895461-3CF5E848-3511-4B21-8990-2FA5AC6B9E11 Q53733893-AD6526A1-6BB9-4C43-AA66-37456CEFEFA9 Q54112898-59831AD3-A427-4B67-8F39-ADB237AE14C8 Q54940165-247B7CCA-4CFB-490B-9A43-81D6D507DE5C Q55124984-5BBC43D7-CCF8-42BC-9A99-4002CD0F2261 Q57106487-E5D3DB47-AA76-472B-B8D3-CE1BDE9A027D Q57106504-446C63A7-E836-4D16-9006-DC64A9697C28 Q57108908-EA5DB540-9350-4B4B-B005-4E93C5231F0A Q57809635-BD6CF139-0DB9-42A6-98CE-6C553207D583

P2860

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Item

http://www.wikidata.org/entity/Q37045421

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs